| Autor: |
Geratz JD; School of Medicine, Department of Pathology, University of North Carolina, Chapel Hill 27599., Tidwell RR, Lombardy RJ, Schwab JH, Anderle SK, Pryzwansky KB |
| Jazyk: |
angličtina |
| Zdroj: |
The American journal of pathology [Am J Pathol] 1991 Oct; Vol. 139 (4), pp. 921-31. |
| Abstrakt: |
Previously bis(5-amidino-2-benzimidazolyl)methane (BABIM) was identified as a strong inhibitor of the multisystem inflammatory disease induced in Lewis rats by injection of streptococcus group A cell wall-derived peptidoglycan polysaccharide (PG-APS). A BABIM derivative, trans-bis(5-amidino-2-benzimidazolyl)ethene (BBE), has attracted attention because of striking qualitative and quantitative differences in its activities when compared with the parent compound. BBE could control destructive tibial osteitis and necrotizing granulomatous splenitis and hepatitis, regardless if given in a preventive or curative mode. The compound had little effect on synovitis, however. BABIM, on the other hand, was active against synovitis and osteitis, but not against splenic granuloma formation. To be effective, it needed to be applied in a preventive mode. BBE caused a characteristic enlargement of PG-APS-laden splenic and hepatic macrophages suggesting that those cells represent targets of the inhibitor. BBE may be a powerful tool for the study of granulomatous lesions. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
